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Despite their side-effects and the advent of systemic immunosuppressives and biologics, the use of corticosteroids
remains in the management of patients with uveitis, particularly when inflammation is associated with systemic
disease or when bilateral ocular disease is present. The use of topical corticosteroids as local therapy for anterior
uveitis is well-established, but periocular injections of corticosteroid can also be used to control mild or moderate
intraocular inflammation. More recently, intraocular corticosteroids such as triamcinolone and steroid-loaded vitreal
inserts and implants have been found to be effective, including in refractory cases. Additional benefits are noted
when ocular inflammation is unilateral or asymmetric, when local therapy may preclude the need to increase the
systemic medication.
Implants in particular have gained prominence with evidence of efficacy including both dexamethasone
and fluocinolone loaded devices. However, an appealing avenue of research lies in the development of
non-corticosteroid drugs in order to avoid the side-effects that limit the appeal of injected corticosteroids.
Several existing drugs are being assessed, including anti-VEGF compounds such as ranibizumab and bevacizumab,
anti-tumour necrosis factor alpha antibodies such as infliximab, as well as older cytotoxic medications such as
methotrexate and cyclosporine, with varying degrees of success. Intravitreal sirolimus is currently undergoing phase
3 trials in uveitis and other inflammatory pathways have also been proposed as suitable therapeutic targets.
Furthermore, the advent of biotechnology is seeing advances in generation of new therapeutic molecules such as
high affinity binding peptides or modified high affinity or bivalent single chain Fab fragments, offering higher
specificity and possibility of topical delivery.Introduction
Inflammatory eye disease encompasses a wide range of
clinical phenotypes, and uveitis can be classified anatom-
ically into either anterior, intermediate and posterior
uveitis or panuveitis; and as acute or chronic disease,
depending on whether it lasts more or less than 3
months in duration [1]. The Standardisation of Uveitis
Nomenclature (SUN) criteria now form the standard for
reporting uveitis clinical data [2]. The commonest type
is acute anterior uveitis, in which 50% of people are
HLA B27 positive, although they do not necessarily have
an associated systemic disorder [3]. Chronic anterior
uveitis lasts longer than 3 months and may or may not
be associated with systemic disease. The rest of the dis-
orders tend to be chronic, and the more serious types* Correspondence: s.r.taylor@imperial.ac.uk
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distribution, and reproduction in any mediumwith posterior segment involvement have an increased
incidence of visual loss, and approximately half of these
patients have an associated systemic disease.
Corticosteroids remain the mainstay of treatment of all
types of uveitis. Anterior uveitis is treated to control
symptoms of pain, photophobia and redness, and to re-
duce complications such as posterior synechiae, cataract
and macular oedema. Posterior segment inflammation
usually requires treatment as it generates sight-threatening
sequelae such as retinitis, macular oedema, optic disc
oedema, chorioretinitis and retinal vasculitis. Topical
corticosteroids are inadequate for this as they do not
penetrate beyond the lens, so oral corticosteroids and
second-line immunosuppressive agents are used, particu-
larly in patients with an associated systemic disease and in
those with bilateral ocular inflammation requiring treat-
ment. Nevertheless, systemic administration is associated
with significant side-effects, so there has been increasingentral Ltd. This is an Open Access article distributed under the terms of the
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periocular tissues in order to avoid these complications.
This approach is not new. Traditionally, periocular
injections of corticosteroids such as triamcinolone and
methlyprednisolone have proved effective in controlling
vitritis and mild to moderate macular edema in unila-
teral disease, but their use is limited by the need for
repeat injections, IOP rises in corticosteroid responders
and the induction of ptosis, orbital fat atrophy or orbital
fat protrusion as a consequence of both the corticos-
teroid and the mode of injection [4,5]. More recently,
intraocular delivery of corticosteroids has become wide-
spread. Initially triamcinolone was used, but long-acting
inserts are now becoming available, e.g. Retisert (Bausch
& Lomb, Rochester, NY, USA) and Ozurdex (Allergan,
Irvine, CA, USA).
Nevertheless, the local side-effects of corticosteroid
delivery remain. Care also needs to be taken in cases of
diagnostic uncertainty to ensure that there is not an in-
fective cause for the uveitis, as this may be worsened by
local therapy and depot corticosteroids can be difficult
to remove, whereas oral corticosteroids can be rapidly
stopped.
Owing to these side-effects, researchers have tried to
move towards new non-corticosteroid alternatives. Some
of these are old drugs, such as methotrexate, and others
are based on the new so-called biological agents, in which
monoclonal antibodies are directed against specific targets
within the immune system, such as the anti-tumour ne-
crosis factor (TNF)-alpha agents and the anti-vascular
endothelial growth factor (VEGF) agents. This review art-
icle aims to outline agents currently in use for the local
therapy of non-infectious uveitis, as well as those currently
in translation from the laboratory to clinical use.
Review
Topical and subconjunctival therapy for ocular
inflammatory disease
Topical corticosteroids have provided the mainstay of
treatment for anterior uveitis since the 1950s, but do not
penetrate far enough into the eye to control intermediate
or posterior disease [6]. Their side-effects include cata-
ract formation and raised intraocular pressure, in com-
mon with all corticosteroids, and are related to the
strength of the corticosteroid and ocular penetration [6].
Corticosteroids
Dexamethasone sodium 0.1% and prednisolone acetate
1% are widely used and are broadly equivalent; diflu-
prednate 0.05% has recently been introduced to the US
and is considered more potent [7]. Rimexolone is a
topical corticosteroid that was specifically engineered to
generate less of an intraocular pressure rise by the elimi-
nation of a hydroxyl group. Randomised ControlledTrials (RCTs) suggest that it probably does induce less
of a rise in intraocular pressure than either dexametha-
sone sodium 0.1% or prednisolone acetate 1% (the differ-
ences did not reach statistical significance [8]), but it is a
weaker corticosteroid that is most useful in controlling
chronic anterior uveitis in patients with established glau-
coma or who are corticosteroid responders. Similarly,
loteprednol etabonate 0.5% is associated with less of an
intraocular pressure rise than prednisolone acetate 1%
[9], but also has a reduced ability to control anterior
chamber inflammation [9].
Subconjunctival corticosteroids in the form of dexa-
methasone or betamethasone may also be useful in the
short-term treatment of severe anterior uveitis [10], and
triamcinolone has recently been shown to be effective in
the management of anterior scleritis without inducing
necrotising disease, having a longer duration of effect
than dexamethasone and betamethasone [11].
Non-steroidal anti-inflammatory drugs
Cyclooxygenase is a critical enzyme in the inflammatory
process and catalyzes the biosynthesis of prostaglandins
that disrupt the blood-ocular barrier, increase vasodilation,
and facilitate leukocyte migration [12]. Non-steroidal anti-
inflammatory drugs (NSAIDs) are potent inhibitors of
cyclooxygenase enzymes and can be administered topi-
cally for the treatment of postoperative inflammation and
macular oedema, either with or without concurrent corti-
costeroid administration [13].
Other agents
There are no other topical anti-inflammatory agents in
widespread use for the treatment of uveitis. Topical Cyclo-
sporine A was examined in several studies from the 1980s
[14,15], but was shown to be ineffective in human disease.
A study of the subconjunctival administration of sirolimus
for intermediate or posterior uveitis was recently reported
in which it was found to be safe and well tolerated (see
Section “Anti-Tumour Necrosis Factor (TNF)-α agents”
below) [16]; the results of a Phase 3 trial are awaited.
Periocular therapy for ocular inflammatory disease
The numerous side-effects of oral corticosteroids are
well-known and include gastric ulcers, weight gain, psy-
chological disturbances, osteoporosis, diabetes, hyper-
tension and suppression of growth in children [17]. In
patients with unilateral or asymmetric disease, or in
whom systemic administration of medication is less
desirable, e.g. during pregnancy or in patients with a
history of gastric ulceration, periocular injection can be
useful to provide a depot of corticosteroid that success-
fully reaches the posterior segment to control inflamma-
tion [18-20].
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The precise mechanisms by which locally injected
corticosteroids enter the eye are not known [21], but
systemic drug levels remain low, and corticosteroids can
be found in all layers of the eye, even at 30 days after a
single subtenon injection of 40 mg of triamcinolone
acetate, the highest levels being found in the choroid
and retinal pigment epithelium [22]. Periocular cortico-
steroid injections can be administered either via the
subtenon route or as an orbital floor injection [18]. Both
procedures are safe, with a low risk of ocular penetration
and of developing other side-effects of corticosteroid
administration such as raised intraocular pressure and
cataract [23-25]. The duration of effect is approximately
2 months [26].
Other periocular agents
Currently no other non-corticosteroid agents are injec-
ted periocularly for the treatment of ocular inflammatory
disease.
Intraocular corticosteroid therapy for ocular inflammatory
disease
Intravitreal injections are now commonplace in ophthal-
mology, and are used for the treatment for a variety of
ocular inflammatory and medical retinal disorders. The
injection of dexamethasone into the vitreous had pre-
viously been used as an adjunct to vitrectomy, but it
remains in the eye at therapeutic levels for hours only
[27,28], and thus was superseded by triamcinolone as
the intravitreal corticosteroid of choice. Triescence and
Trivaris are triamcinolone preparations that are licenced
for intraocular use in the US, but neither is available in
the Europe, and Kenalog is commonly used off-label
instead. However triamcinolone has a considerable
side-effect profile in terms of cataract formation and
raised intraocular pressure [29]. The injection-related
side effects of intravitreal therapy resemble those of any
other intraocular injection, and include endophthal-
mitis, intravitreal haemorrhage, rhegmatogenous retinal
detachment, although these are rare. Other corti-
costeroid and non-corticosteroid agents have subse-
quently been developed, including sustained-release
implants.
Intravitreal corticosteroid injections
Intravitreal injection of triamcinolone acetate (IVTA) in
the treatment of uveitis is now commonplace, and
involves the injection of corticosteroid directly into the
vitreous body, thus achieving a higher concentration of
intraocular corticosteroid [30]. The consensus for the
recommended dosage of IVTA is 4mg, and the typical
duration of effect is 3–4 months [31,32]. IVTA is most
commonly used for the treatment of inflammatorycystoid macular oedema [33,34]. The systemic side-
effects of IVTA are limited, as the triamcinolone is con-
fined to the eye and serum levels have been shown not
to be significant [35], but raised intraocular pressure is
seen in 29-50% of patients within a year [33]. In most
cases this can be controlled medically, but there have
been a few reports of patients requiring surgical inter-
vention [36]. Cataract development is also a common
side-effect of IVTA in uveitic patients, and the rate of
cataract progression is reported to be increased five-fold,
particularly after multiple injections [29].
Short- and medium-acting intravitreal corticosteroid implants
The Surodex anterior segment delivery system (Oculex
Pharmaceuticals, Sunnyvale, CA, USA) was designed to
control inflammation after cataract surgery, and consists
of a biodegradable device that is inserted into the anter-
ior chamber and allows sustained release of corticos-
teroid over a period of seven days. It contains 60 μg
dexamethasone incorporated into a polymer matrix of
poly(lactic-glycolic)-acid, and achieves higher intraocular
drug levels than conventional dexamethasone eye drops
[37]. It is effective in the control of post-cataract surgery
inflammation [37-39] but, as it only lasts for seven days,
its usefulness does not extend beyond post-operative
uveitis, and is not in widespread use.
The Ozurdex ‘bio-erodible’ dexamethasone implant is
now licensed for the treatment of uveitis in the USA and
Europe. This uses a solid polymer delivery system, in
which biodegradable material is combined with dexa-
methasone to form a small rod-shaped implant which is
injected into the vitreous using a specially designed
injector. Dexamethasone is released over about 6 months,
the pharmacokinetics demonstrating a high initial con-
centration peak in the vitreous followed by a longer
period of low-level release before the implant dissolves
completely to H2O and CO2, leaving no residue [40].
This has been shown to be effective in both adult [41]
and paediatric [42] uveitis and it is hoped that it will
cause less raised intraocular pressure and cataract than
triamcinolone, but the phase III trial included only one
implant and excluded steroid responders. Further data
are awaited.
Long-acting intravitreal corticosteroid implants
Retisert is a long-term slow release intravitreal implant,
which was based on those used to deliver ganciclovir to
patients with cytomegalovirus retinitis, but which is
smaller in size. The chosen corticosteroid is fluocinolone
acetonide as it has high potency, low solubility and a
very short duration of action in the systemic circulation,
enabling the steroid pellet to be small, and reducing the
risk of systemic side-effects. The implant is surgically
placed into the vitreous cavity and pharmacokinetic
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stant levels of the corticosteroid to the posterior pole
with no evidence of systemic absorption over approxi-
mately 2.5 years [43,44].
Its efficacy has been demonstrated in large studies
[45], but it induces marked cataract formation such that
all patients require cataract surgery within 3 years [45].
Significantly raised intraocular pressure is also very com-
mon, with up to 40% of patients requiring trabeculec-
tomy surgery [45]. Additional side-effects include scleral
thinning over the implant in some cases, vitreous band
formation, and the development of cytomegalovirus
retinitis and endotheliitis [46]. In view of its effects
on intraocular pressure and cataract, it is worth not-
ing that insertion of the implant can be combined
safely with glaucoma drainage device placement [47]
or with phacoemulsification and intraocular lens in-
sertion [48].
The Multicenter Uveitis Steroid Treatment (MUST)
trial compare local control of intermediate and posterior
uveitis with Retisert implants (implanted bilaterally for
bilateral disease) with aggressive oral systemic therapy,
and found no significant differences between each treat-
ment arm at two years in terms of vision, although
macular oedema did appear to be better controlled in
the implant arm [49]. The trial has recently been ex-
tended for a further four years to see whether significant
differences emerge over a longer timespan.
Other intravitreal corticosteroid inserts
Iluvien (Alimera Sciences, Alpharetta, GA, USA) is an-
other fluocinolone acetonide intravitreal insert which is
designed to deliver corticosteroid to the retina for up to
three years as a treatment for diabetic macular oedema
[50]. It uses the same drug matrix as Retisert, but is
thought to release a lower dose of drug (0.2 μg/day or
0.5 μg/day) than Retisert (nominally 0.59 μg/day) [50],
and is injected through a proprietary 25-gauge injector
system in an outpatient setting, in contrast to the surgi-
cal setting required to implant the Retisert device. Phase
II studies in diabetic macular oedema suggest the possi-
bility of a lower rate of IOP rise than with Retisert,
although the numbers in the study were relatively small,
the follow-up period short, and there was still significant
incidence of cataract progression, suggesting the oc-
currence of significant corticosteroid side-effects [51].
There is no published evidence for its use in uveitis.
The I-Vation implant (SurModics, Eden Prairie, MN,
USA) is based around triamcinolone, and is reported
to have a duration of release of over a year. It has a
unique implantation mechanism in which a screw-
shaped device is twisted through the pars plana, al-
though little published data is currently available on
its use [50,52].Intravitreal non-corticosteroid therapy for ocular
inflammatory disease
In an attempt to avoid the ocular side-effects of intraoc-
ular corticosteroids, attention has been focused on the
development of other agents. This has involved the trial
of both established immunosuppressive agents and also
the novel so-called biological therapies, with varying
degrees of success.
Non-steroidal anti-inflammatory drugs
Ketorolac does not reach significant levels in the vitreous
or retina after topical or systemic application [12,53]. A
recent prospective phase I trial of intravitreal ketorolac
in ten patients showed some effect in treating intrao-
cular inflammation and macular oedema [54]. However,
a similar pilot study of intravitreal diclofenac showed
no benefit [55].
Conventional immunosuppressive agents
Intraocular methotrexate has long been used to treat
intraocular lymphomas associated with primary central
nervous system lymphoma [56,57], but has more re-
cently been tried in uveitis [58,59]. In one prospective
study it was found to be effective in reducing vitritis and
macular oedema without raising the IOP in patients with
a history of steroid response. Interestingly, the onset of
effect was within one week and lasted approximately
three months, with no statistical difference between the
best visual acuity obtained after methotrexate injection
and after previous corticosteroid treatment, including
IVTA injection [59]. A larger collaborative series is cur-
rently in press and has suggested that this drug may
induce longer-term remission in some patients [60,61].
There is some published evidence of the successful use
of cyclosporine-loaded poly(lactic co-glycolic) spheres in
animal models [62], but this has not been successfully
translated into the treatment of human disease. Intravit-
real tacrolimus has shared a similar fate [63,64].
Anti-vascular endothelial growth factor (VEGF) agents
VEGF inhibition has also been tried as a non-
corticosteroid intraocular treatment for uveitic CME,
owing to its induction in inflammation, its role in
increasing vascular permeability and the finding of
increased levels in eyes with uveitic macular oedema
[65-69]. Several small retrospective studies have been
reported using both bevacizumab and ranibizumab,
although bevacizumab is more commonly used owing to
its lower cost. Intravitreal bevacizumab does appear
effective in reducing central macular thickness, but the
studies do not generally suggest a statistically significant
increase in visual acuity [65,70,71]. Similar results have
been achieved with ranibizumab [72].
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anti-VEGF treatment to IVTA in the treatment of
uveitis-associated CME. Two retrospective reports com-
prising 31 eyes treated with IVTA and 26 eyes treated
with intravitreal bevacizumab indicated a trend for better
visual improvement and decreased macular thickness in
IVTA-treated eyes [73,74]. A further prospective report
with longer follow-up indicated an improved visual out-
come for eyes treated with IVTA, once the confounding
effect of cataract had been removed [75].
Similar to methotrexate, anti-VEGF agents have the
advantage over IVTA of being much less likely to cause
cataract progression or a rise in IOP. However, they have
less anti-inflammatory effect, making them less suitable
for the treatment of CME primarily driven by inflamma-
tion [76] or if there is extensive breakdown of the blood-
retina barrier [65]. The risk of serious cardiovascular
events also remains controversial [77,78].
Anti-tumour necrosis factor (TNF)-α agents
Local inhibition of TNF-α is a new and promising thera-
peutic direction, but clinical trials in patients have had
mixed results. The initial rationale for injecting anti-
TNF-α drugs intraocularly was their efficacy when used
systemically, even though their purported mechanism of
action may not be effective when delivered locally
[79-82]. Infliximab is a humanized, chimeric monoclonal
antibody directed against TNF-α and clinical experience
with its intravitreal use in uveitis is limited to one small
pilot study of 10 eyes with chronic non-infectious uveitis
that were unresponsive to systemic steroids [83]. Intra-
vitreal injection of 1.5 mg infliximab led to significant
improvements in best corrected visual acuity, with a
significant decrease in the central macular thickness and
vitreous haze grading, but the follow-up period in this
study was very short at four weeks. However, in one
study in which 0.5 mg infliximab was injected for either
diabetic macular oedema or neovascular age related
macular degeneration, intraocular inflammation deve-
loped in three of four treated eyes [84], and in another
study in which eyes with refractory diabetic macular
oedema were treated with 1–2 mg infliximab, 42% of
eyes receiving the 2mg dose developed severe uveitis,
most of which subsequently required pars plana vitrec-
tomy [85]. Not surprisingly, there has been a call for a
moratorium on the clinical use of intravitreal infliximab
outside of well-designed trials [86].
Adalimumab, a humanized monoclonal antibody against
the soluble and membrane-bound TNF has recently been
considered for intravitreal injection. Evidence of safety has
been reported in rabbits [87], but clinical use in uveitic
CME is limited to one small study of 8 eyes that were
unresponsive to treatment with intraocular steroids and
anti-VEGF injection. While there were no safety concernswith a dose of 1 mg, it failed to produce any significant
improvement in vision or reduction of macular thickness
[88]. Pre-clinical studies of the TNF inhibitor ESBA105
have also suggested good intravitreal and neuroretinal
bioavailability [89], and it may be that newer agents can
overcome the problems seen with the older chimeric
antibody infliximab.
Sirolimus
Sirolimus, also known as rapamycin, was isolated in the
1970s from Streptomyces hygroscopicus in soil samples
from Easter Island [90]. It is an immunosuppressant that
works through inhibition of the mammalian target of
rapamycin (mTOR) by binding to the immunophilin FK
protein 12 (FKBP-12), and thus interrupts the inflamma-
tory cascade that leads to T-cell activation and prolifera-
tion. It also suppresses T-cell proliferation through the
inhibition of IL-2, IL-4, and IL-15 via both calcium-
dependent and calcium-independent pathways [91]. A
study of intravitreal and subconjunctival administration
of sirolimus in 30 patients was recently reported in
which it was reported to be safe and tolerable [16]. The
results of a Phase III trial are currently awaited.
Future directions
Local treatment remains an attractive therapeutic option
for uveitis, as it has the potential for avoiding systemic
adverse events. Research continues into developing novel
corticosteroids that maintain their anti-inflammatory
effects whilst having an improved ocular side-effect
profile, but the greatest hope must lie in the deve-
lopment of non-corticosteroid therapeutic options. In
support of this goal, understanding of the pathophysi-
ology of uveitis has advanced over the past decade, and
mechanisms of ocular damage are increasingly being
understood [92,93].
This is particularly true in the broad context of
Matzinger’s danger hypothesis, which helps to explain
the ways in which the immune system is designed to
detect self from non-self [94]. Non-infectious uveitis is
generally understood as representing an autoimmune
phenomenon, but experimental non-infectious uveitis
requires initial activation of innate immunity prior to
the generation of specific T cell responses, and there is
good evidence to suggest that this also applies in human
disease [92]. This presents a therapeutic opportunity as
autoimmunity and autoinflammation evoke different
molecular pathways that may generate different potential
molecular targets. For example, improved understanding
of how danger is sensed by the immune system, and
how inflammasomes are subsequently involved in the
activation of caspase-1 to release IL-1β and IL-18 [95]
leads to the potential for anti-IL-1 or anti-caspase-1 thera-
pies in some uveitic conditions [96]. Short interfering
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which to target caspases, and caspase-2 has already been
targeted successfully in an animal model of retinal gan-
glion cell loss [97]. Similarly, it may be possible to block
pro-inflammatory cytokines such as IL-1β and IL-6 locally
[89], or to target upstream so-called danger sensors, such
as the purinergic ATP receptors [98], or even cell function
regulators such as the sirtuins [99].
Other promising strategies include preventing cells
from entering the target organ by inhibition of either
adhesion or migration through endothelium (anti-α4-integ-
rin (natalizumab)) [100], or via preventing efflux from
lymph nodes by blocking sphingosine-1-phosphate receptor
(fingolimod) [101], or targeting other effector cells, such as
macrophages, through complement inhibition or stimula-
tion of the CD200 macrophage inhibitory receptor. Anti-
CD20 (rituximab) has also shown efficacy when given
systemically for orbital inflammation [102,103], although it
has not been used intravitreally other than for lymphoma
[104], and the efficacy of some of these treatments is help-
ing to illuminate novel mechanistic pathways and challenge
previous understanding of disease pathophysiology.
Furthermore, the advent of biotechnology is seeing
advances in generation of new therapeutic molecules such
as high affinity binding peptides or modified high affinity or
bivalent single chain Fab fragments, offering higher specifi-
city and possibility of topical delivery. For instance, the
TNF-α inhibitory single-chain antibody fragment ESBA105
has been shown to reach therapeutic levels in all ocular
compartments following topical administration in rabbits
[105], and it is hoped that it will be possible to translate
similar technology into clinical use. Indeed, the ability to
deliver effective uveitis therapy to the posterior segment
through the topical route truly would provide a step change
to the advantages of local therapy.
Conclusions
In conclusion, the eye offers both a unique window on the
functioning of the immune system and a unique opportun-
ity for the effective local treatment of autoimmune and
autoinflammatory disorders. Given the plethora of potential
mechanisms and associated targets that increased under-
standing of its pathophysiology has introduced, it seems
unlikely that the long-term future of therapy lies in cortico-
steroids, but instead that this increased knowledge will offer
the opportunity for effective targeted treatment of the mo-
lecular mechanisms underlying ocular inflammation whilst
minimising local and systemic side-effects.
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